BPC 157 10 MG (prefilled syringes) and the broader category Peptides
Before generics become available on the market, the generic company must prove it has the same active ingredients as the brand-name drug and works in the same way and in the same amount of time in the body
[DOI] [Google Scholar] 12.Staresinic M., Japjec M., Vranes H., Prtoric A., Zizek H., Krezic I., Gojkovic S., Smoday I.M., Oroz K., Staresinic E., et al
Eric Topol of Scripps Research Translational Institute was more direct: "These peptides have no data to support their safety and efficacy." The clinical proponents argue that the FDA's safety concerns immunogenicity risk, impurity risk, organ toxicity are theoretically valid but speculative in practice